One shot to lower blood pressure? early trial begins
NCT ID NCT07614308
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a single injection of ART101 in 16 adults with high blood pressure. The goal is to see if it is safe and how it affects blood pressure over 24 weeks. Participants receive either 600 mg or 800 mg of the drug and are closely monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ART101 injection
- What this could lead to
- If successful, this could point toward a new injectable treatment for high blood pressure that requires only a single dose.
- What could go wrong
- This is a very early Phase 1 trial with only 16 people, so safety and effectiveness are not yet proven. The treatment may not lower blood pressure enough or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Suzhou Arnatar Therapeutics Co., Ltd
Suzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a heart drug be a new key to controlling high blood pressure?
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can a Partner-Powered program tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?